PBYI SEC申報文件 - Puma Biotechnology, Inc.-年度報告，委任書，招股章程

基本數據

CIK

1401667

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Puma Biotechnology, Inc.

SEC Filings (Chronological Order)

本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。

May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PUMA BIOTECHNOLOGY, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PUMA BIOTECHNOLOGY, INC.
May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PU
May 7, 2026	EX-10.1	NINTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FIFTH AMENDMENT TO DISCLOSURE LETTER Exhibit 10.1 Execution Version NINTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FIFTH AMENDMENT TO DISCLOSURE LETTER This NINTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FIFTH AMENDMENT TO DISCLOSURE LETTER (this “Agreement”), dated as of April 16, 2026, is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party here
May 7, 2026	EX-99.1	Puma Biotechnology Reports First Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter 2026 Financial Results Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX LOS ANGELES, Calif., May 7, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2026. Unless otherwise stated, all comparisons are for t
April 28, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 28, 2026	ARS	FORM ARS POSSIBILITIES 2025 Annual Report Puma Biotechnology, Inc. Scaling NewPuma is seeking new heights with its promising therapy, Alisertib—offering hope and improved outcomes for patients in need. Puma is scaling new heights with its continued commercial execution of NERLYNX® and with development of its investigational drug alisertib.PHASE I PHASE II PHASE III REGISTRATION APPROVAL * EBC: Early breast
April 28, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
April 7, 2026	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
February 26, 2026	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiary Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology B.V. Netherlands
February 26, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 PUMA BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 PUMA BIOTECHNOLOGY, INC.
February 26, 2026	EX-19.1	Puma Biotechnology, Inc. Insider Trading Compliance Policy Exhibit 19.1 Puma Biotechnology, Inc. Insider Trading Compliance Policy Federal laws and regulations prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws and regulations also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trad
February 26, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35
February 26, 2026	EX-10.7	Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Effective April 1, 2026) Exhibit 10.7 Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Effective April 1, 2026) Non-employee members of the board of directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in th
February 26, 2026	EX-4.3	Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.3 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Except as otherwise indicated herein or as the context otherwise requires, references in this exhibit to “we,” “us,” “our” and “our company” refer to Puma Biotechnology, Inc. The following description of our common stock and certain provisions of our second amended and re
February 26, 2026	EX-99.1	Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results LOS ANGELES, Calif., Feb. 26, 2026 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the
November 6, 2025	EX-10.1	EIGHTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FOURTH AMENDMENT TO DISCLOSURE LETTER Exhibit 10.1 Execution Version EIGHTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FOURTH AMENDMENT TO DISCLOSURE LETTER This EIGHTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND FOURTH AMENDMENT TO DISCLOSURE LETTER (this “Agreement”), dated as of October 6, 2025, is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party
November 6, 2025	EX-99.1	Puma Biotechnology Reports Third Quarter 2025 Financial Results Raising 2025 NERLYNX® revenue and net income estimates Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2025 Financial Results Raising 2025 NERLYNX® revenue and net income estimates LOS ANGELES, Calif., Nov. 6, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2025. Unless otherwise stated, all comparisons are for the third quarter of 202
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 PUMA BIOTECHNOLOGY, INC.
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3570
August 7, 2025	EX-10.1	Fifth Amendment to Office Lease, dated as of October 27, 2017, by and between the Company and DE PARK AVENUE 10880, LLC Exhibit 10.1 FIFTH AMENDMENT TO OFFICE LEASE This Fifth Amendment to Office Lease (this "Fifth Amendment"), dated October 27, 2017, is made by and between DE PARK AVENUE 10880, LLC, a Delaware limited liability company ("Landlord"), with offices at 808 Wilshire Boulevard, Suite 200, Santa Monica, California 90401, and PUMA BIOTECHNOLOGY, INC., a Delaware corporation ("Tenant"), with offices at 108
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PUMA BIOTECHNOLOGY, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 PUMA BIOTECHNOLOGY, INC.
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUM
August 7, 2025	EX-10.2	Sixth Amendment to Office Lease, dated as of July 23, 2025, by and between the Company and DE PARK AVENUE 10880, LLC Exhibit 10.2 SIXTH AMENDMENT TO OFFICE LEASE This Sixth Amendment to Office Lease (this “Sixth Amendment”), dated July 23, 2025 (the “Sixth Amendment Effective Date”), is made by and between DE PARK AVENUE 10880, LLC, a Delaware limited liability company (“Landlord”), with offices at 1299 Ocean Avenue, Suite 1000, Santa Monica, California 90401, and PUMA BIOTECHNOLOGY, INC., a Delaware corporation
August 7, 2025	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No.1 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUM
August 7, 2025	EX-99.1	Puma Biotechnology Reports Second Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter Financial Results LOS ANGELES, Calif., Aug. 7, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2025. Unless otherwise stated, all comparisons are for the second quarter 2025 compared to the second quarter 2024. Product revenue, net consi
June 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2025 PUMA BIOTECHNOLOGY, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2025 PUMA BIOTECHNOLOGY, INC.
June 24, 2025	EX-3.1	Fifth Amended and Restated Bylaws of Puma Biotechnology, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED BYLAWS OF PUMA BIOTECHNOLOGY, INC. (a Delaware Corporation) ARTICLE I STOCKHOLDERS Section 1. Certificates Representing Stock. (a) Certificates representing stock in Puma Biotechnology, Inc. (the “Corporation”) shall be signed by, or in the name of, the Corporation by two officers of the Corporation, including by the Treasurer or an Assistant Treasurer or the
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 PUMA BIOTECHNOLOGY, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 PUMA BIOTECHNOLOGY, INC.
May 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PUMA BIOTECHNOLOGY, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PUMA BIOTECHNOLOGY, INC.
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PU
May 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PUMA BIOTECHNOLOGY, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PUMA BIOTECHNOLOGY, INC.
May 8, 2025	EX-99.1	Puma Biotechnology Reports First Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter Financial Results LOS ANGELES, Calif., May 8, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the first quarter of 2025 compared to the first quarter of 2024. Product revenue, net con
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
April 28, 2025	ARS	ARS Puma Biotechnology, Inc. \| 2024 Annual Report D DEVELOPMENT D R I V E N B Y DRIVEN BY For patients in need For patients in needP PUMA’S GROWTH T H E N E X T P H A S E O F THE NEXT PHASE OF W I L L B E D R I V E N B Y T H E C L I N I C A L WILL BE DRIVEN BY THE CLINICAL D E V E L O P M E N T O F A L I S E R T I B DEVELOPMENT OF ALISERTIBPUMA BIOTECHNOLOGY, INC. is a biopharmaceutical company with a
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35
February 27, 2025	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiary Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology B.V. Netherlands
February 27, 2025	EX-99.1	Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results LOS ANGELES, Calif., Feb. 27, 2025 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the
February 27, 2025	EX-10.2N	Form of Restricted Stock Unit Award Agreement, issued pursuant to the 2017 Employment Inducement Award Plan Exhibit 10.2n PUMA BIOTECHNOLOGY, INC. 2017 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Puma Biotechnology, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Employment Incentive Award Plan (as may be amended from time to time, the “Plan”), hereby grants to the holder listed below (the “Participant”) an award of restricted stock units (the
February 27, 2025	EX-19.1	Insider Trading and Compliance Policy Exhibit 19.1 Puma Biotechnology, Inc. Insider Trading Compliance Policy Federal laws and regulations prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws and regulations also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trad
February 27, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 PUMA BIOTECHNOLOGY, INC.
February 14, 2025	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2025 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Puma Biotechnology, Inc. Date: February 14, 2025 FRAZIER LIFE SCIENCES PUBLIC FUND, L.P. By: FHML
February 3, 2025	EX-99.1	JOINT FILING AGREEMENT EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.
November 8, 2024	SC 13G	PBYI / Puma Biotechnology, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us74587v1070110824.txt us74587v1070110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PUMA BIOTECHNOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74587V107 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b
November 7, 2024	EX-99.1	Puma Biotechnology Reports Third Quarter 2024 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2024 Financial Results LOS ANGELES, Calif., Nov. 7, 2024 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenu
November 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3570
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 PUMA BIOTECHNOLOGY, INC.
October 22, 2024	SC 13G	PBYI / Puma Biotechnology, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us74587v1070102224.txt us74587v1070102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PUMA BIOTECHNOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74587V107 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate b
September 16, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 PUMA BIOTECHNO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35703 77-0683487 (State or other jurisdiction of incorporation) (Commis
August 27, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Puma Biotechnology, Inc.
August 27, 2024	S-8	As filed with the Securities and Exchange Commission on August 27, 2024 As filed with the Securities and Exchange Commission on August 27, 2024 Registration No.
August 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 PUMA BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35703 77-0683487 (State or other jurisdiction of incorporation) (Commissio
August 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35703 77-0683487 (State or other jurisdiction of incorporation) (Commission
August 1, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 PUMA BIOTECHNOLOGY, INC.
August 1, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUM
August 1, 2024	EX-99.1	Puma Biotechnology Reports Second Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter Financial Results LOS ANGELES, Calif., Aug. 1, 2024 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consi
June 24, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 PUMA BIOTECHNOLOGY, INC.
June 24, 2024	EX-10.1	Sixth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan Exhibit 10.1 SIXTH AMENDMENT TO PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN This Sixth Amendment (“Sixth Amendment”) to the Puma Biotechnology, Inc. 2011 Incentive Award Plan, as amended (the “Plan”), is adopted by the Board of Directors (the “Board”) of Puma Biotechnology, Inc., a Delaware corporation (the “Company”), effective as of June 18, 2024 (the “Amendment Effective Date”). Capitali
May 17, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35703 77-0683487 (State or other jurisdiction of incorporation) (Commission F
May 2, 2024	EX-10.1	Seventh Amendment to Note Purchase Agreement and Third Amendment to Disclosure Letter, dated April 12, 2024, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent Exhibit 10.1 SEVENTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND THIRD AMENDMENT TO DISCLOSURE LETTER This SEVENTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND THIRD AMENDMENT TO DISCLOSURE LETTER (this “Agreement”), dated as of April 12, 2024, is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIU
May 2, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 PUMA BIOTECHNOLOGY, INC.
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PU
May 2, 2024	EX-99.1	Puma Biotechnology Reports First Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter Financial Results LOS ANGELES, Calif., May 2, 2024 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product revenue, net consists
April 26, 2024	ARS	ARS EXPANDING OUR HORIZONS Puma Biotechnology, Inc. \| 2023 Annual Report Puma Biotechnology, Inc. \| 2023 Annual ReportPuma is committed to improving the lives of patients who continue to inspire and motivate us in our mission.PUMA BIOTECHNOLOGY, INC. is a biopharmaceutical company with a focus on the development and commercialization of in- novative products to enhance cancer care. Puma in-licensed th
April 26, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
April 26, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
March 29, 2024	EX-99.A	AGREEMENT EX-99.A 2 d787776dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of Common Stock of Puma Biotechnology, Inc. Date: March 29, 2024 FRAZIER LIFE SCIENCES PUBLIC FU
March 29, 2024	SC 13G	PBYI / Puma Biotechnology, Inc. / Frazier Life Sciences Public Fund, L.P. - SC 13G Passive Investment SC 13G 1 d787776dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Puma Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587V107 (CUSIP Number) March 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate
March 19, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-35703 77-0683487 (State or other jurisdiction of incorporation) (Commission
February 29, 2024	EX-99.1	Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results LOS ANGELES, Calif., Feb. 29, 2024 — Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2023 compared to the
February 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 PUMA BIOTECHNOLOG UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 PUMA BIOTECHNOLOGY, INC.
February 29, 2024	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology B.V. Netherlands
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35
February 29, 2024	EX-97.1	Puma Biotechnology, Inc. Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 PUMA BIOTECHNOLOGY, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Puma Biotechnology, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to
February 14, 2024	SC 13G/A	PBYI / Puma Biotechnology, Inc. / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 14, 2024	EX-1	JOINT FILING AGREEMENT EX-1 2 CamberPBYI-a13g2024ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2024 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securitie
February 13, 2024	SC 13G/A	PBYI / Puma Biotechnology, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01759-pumabiotechnologyinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Puma Biotechnology Inc Title of Class of Securities: Common Stock CUSIP Number: 74587V107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to
February 6, 2024	SC 13G/A	PBYI / Puma Biotechnology, Inc. / ACORN BIOVENTURES, L.P. - PUMA BIOTECHNOLOGY, INC. Passive Investment SC 13G/A 1 p24-0350sc13ga.htm PUMA BIOTECHNOLOGY, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Puma Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statemen
January 30, 2024	SC 13G/A	PBYI / Puma Biotechnology, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 74587V107 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate th
January 18, 2024	EX-99.1	Presentation of Puma Biotechnology, Inc., dated January 2024. Exhibit 99.1
January 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 PUMA BIOTECHNOLOGY, INC.
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3570
November 2, 2023	EX-10.2	Sixth Amendment to Note Purchase Agreement, dated September 8, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 2, 2023, and incorporated herein by reference) Exhibit 10.2 SIXTH AMENDMENT TO NOTE PURCHASE AGREEMENT This SIXTH AMENDMENT TO NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of September 8, 2023, is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All capitalized ter
November 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 PUMA BIOTECHNOLOGY, INC.
November 2, 2023	EX-99.1	Puma Biotechnology Reports Third Quarter 2023 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2023 Financial Results LOS ANGELES, Calif., Nov. 2, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2023. Unless otherwise stated, all comparisons are for the third quarter of 2023 compared to the third quarter of 2022. Product revenu
September 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 PUMA BIOTECHNOLO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 PUMA BIOTECHNOLOGY, INC.
September 1, 2023	SC 13G	PBYI / Puma Biotechnology Inc / ACORN BIOVENTURES, L.P. - PUMA BIOTECHNOLOGY, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Puma Biotechnology, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 74587V107 (CUSIP Number) August 22, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
August 18, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 PUMA BIOTECHNOLOGY, -12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 PUMA BIOTECHNOLOGY, INC.
August 18, 2023	EX-3.1	s Current Report on Form 8-K filed with the SEC on August 18, 2023, and incorporated herein by reference) Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF PUMA BIOTECHNOLOGY, INC. (a Delaware Corporation) ARTICLE I STOCKHOLDERS Section 1. Certificates Representing Stock. (a) Certificates representing stock in Puma Biotechnology, Inc. (the “Corporation”) shall be signed by, or in the name of, the Corporation by two officers of the Corporation, including by the Treasurer or an Assistant Treasurer or th
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUM
August 3, 2023	EX-99.1	Puma Biotechnology Reports Second Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter Financial Results LOS ANGELES, Calif., Aug. 3, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023. Unless otherwise stated, all comparisons are for the second quarter of 2023 compared to the second quarter of 2022. Product revenue, net
August 3, 2023	EX-10.1	Limited Waiver and Fifth Amendment to Note Purchase Agreement, dated July 7, 2023, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 3, 2023, and incorporated herein by reference) Exhibit 10.1 LIMITED WAIVER AND FIFTH AMENDMENT TO NOTE PURCHASE AGREEMENT This LIMITED WAIVER AND FIFTH AMENDMENT TO NOTE PURCHASE AGREEMENT (this “Agreement”), dated as of July 7, 2023, is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administ
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PUMA BIOTECHNOLOGY, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PUMA BIOTECHNOLOGY, INC.
June 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 PUMA BIOTECHNOLOGY, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 PUMA BIOTECHNOLOGY, INC.
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PUMA BIOTECHNOLOGY, INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PUMA BIOTECHNOLOGY, INC.
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PU
May 4, 2023	EX-99.1	Puma Biotechnology Reports First Quarter Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter Financial Results LOS ANGELES, Calif., May 4, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the first quarter of 2023 compared to the first quarter of 2022. Product revenue, net con
April 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide
April 28, 2023	ARS	ARS TWO DRUGS ONE MISSION ONE MISSION Puma Biotechnology, Inc. \| 2022 Annual Report Expanding Our Pipeline For Patients In NeedPuma is expanding its pipeline and exploring effective treatments for patients in need with the addition of Alisertib.PUMA BIOTECHNOLOGY, INC. is a biopharmaceutical company with a focus on the development and commercialization of in- novative products to enhance cancer care.
April 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
March 2, 2023	EX-10.17C	Second Amendment to Note Purchase Agreement, dated May 18, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.17(c) to the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2023 and incorporated herein by reference) Exhibit 10.17(c) SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT This SECOND AMENDMENT TO NOTE PURCHASE AGREEMENT (the “Agreement”) dated as of May 18, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All capitalized terms
March 2, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35
March 2, 2023	EX-99.1	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results LOS ANGELES, Calif., March 2, 2023 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2022. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2022, compared to the four
March 2, 2023	EX-10.17E	Fourth Amendment to Note Purchase Agreement, dated November 29, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.17(e) to the Company’s Annual Report on Form 10-K filed with the SEC on March 2, 2023 and incorporated herein by reference) Exhibit 10.17(e) FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND SECOND AMENDMENT TO DISCLOSURE LETTER This FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND SECOND AMENDMENT TO DISCLOSURE LETTER (the “Agreement”) dated as of November 29, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the “Issuer”), the Guarantors party hereto, the Purchasers party hereto and ATH
March 2, 2023	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology B.V. Netherlands
March 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 PUMA BIOTECHNOLOGY, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 PUMA BIOTECHNOLOGY, INC.
February 14, 2023	EX-1	JOINT FILING AGREEMENT EX-1 2 camberPBYI-13ga2023ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securitie
February 14, 2023	SC 13G/A	PBYI / Puma Biotechnology Inc / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 9, 2023	SC 13G/A	PBYI / Puma Biotechnology Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Puma Biotechnology Inc. Title of Class of Securities: Common Stock CUSIP Number: 74587V107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file
February 7, 2023	SC 13G/A	PBYI / Puma Biotechnology Inc / GOLDMAN SACHS GROUP INC Passive Investment SC 13G/A 1 PUMABIO.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PUMA BIOTECHNOLOGY, INC. - (Name of Issuer) Common Stock, par value $0.0001 per share - (Title of Class of Securities) 74587V107 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the
January 19, 2023	SC 13G/A	PBYI / Puma Biotechnology Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 74587V107 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate th
January 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PUMA BIOTECHNOLOGY, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 PUMA BIOTECHNOLOGY, INC.
January 9, 2023	EX-99.1	Presentation of Puma Biotechnology, Inc., dated January 2023. EX-99.1 2 ex461383.htm EXHIBIT 99.1 Exhibit 99.1
December 16, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 PUMA BIOTECHNOLOGY, INC.
December 13, 2022	EX-10.1	Securities Purchase Agreement, dated December 9, 2022, by and between Puma Biotechnology, Inc. and Alan H. Auerbach. Exhibit 10.1 PUMA BIOTECHNOLOGY, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (“Agreement”) is made as of December 9, 2022 (the “Agreement Date”), by and among Puma Biotechnology, Inc., a Delaware corporation (the “Company”), and Alan H. Auerbach (the “Purchaser”). AGREEMENT In consideration of the mutual covenants contained in this Agreement, and for other good and valuab
December 13, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 PUMA BIOTECHNOLOGY, INC.
December 13, 2022	SC 13D/A	PBYI / Puma Biotechnology Inc / AUERBACH ALAN H - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) Alan H. Auerbach 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 Telephone : (424) 248-6500 Copy to : B
December 9, 2022	EX-99.1	Presentation Poster of Puma Biotechnology, Inc., dated December 9, 2022. Exhibit 99.1
December 9, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 PUMA BIOTECHNOLOGY, INC.
December 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 PUMA BIOTECHNOLOGY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 PUMA BIOTECHNOLOGY, INC.
December 8, 2022	EX-99.1	Presentation Poster of Puma Biotechnology, Inc., dated December 7, 2022. Exhibit 99.1
December 8, 2022	EX-99.2	Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium Exhibit 99.2 News Release Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium LOS ANGELES, Calif., Dec. 7, 2022 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented updated findings from the Translational Breast Cancer Research Consortium (TBCRC) Trial 022 at the ongoing 2022 San Antonio Breast Cancer Sy
November 10, 2022	EX-99.1	SETTLEMENT AGREEMENT AND RELEASE Exhibit 99.1 SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (the ?Agreement?) is made and entered into effective as of the date of the last signature to this Agreement (the ?Effective Date?), by and among Puma Biotechnology, Inc. (?Puma?) and Fredric N. Eshelman (?Eshelman?), each individually a ?Party? and collectively the ?Parties.? RECITALS WHEREAS, on February 2, 2016,
November 10, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 PUMA BIOTECHNOLOGY, INC.
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3570
November 3, 2022	EX-10.2	Exclusive License Agreement, dated September 16, 2022, by and between the Company and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 3, 2022 and incorporated herein by reference) Exhibit 10.2 Execution Version [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (this ?Agreement?) is entered into as of September [?], 2022 (the ?Effective Da
November 3, 2022	EX-10.1	Third Amendment to Note Purchase Agreement, dated September 16, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 3, 2022 and incorporated herein by reference) Exhibit 10.1 Execution Version THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT This THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT (the ?Agreement?) dated as of September 16, 2022 is entered into by and among PUMA BIOTECHNOLOGY, INC., a Delaware corporation (the ?Issuer?), the Guarantors party hereto, the Purchasers party hereto and ATHYRIUM OPPORTUNITIES IV CO-INVEST 1 LP, as the Administrative Agent. All
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 PUMA BIOTECHNOLOGY, INC.
November 3, 2022	EX-99.1	Puma Biotechnology Reports Third Quarter 2022 Financial Results ● Raises FY 2022 NERLYNX Net Product Revenue Guidance Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2022 Financial Results ? Raises FY 2022 NERLYNX Net Product Revenue Guidance LOS ANGELES, Calif., Nov. 3, 2022 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2022. Unless otherwise stated, all comparisons are for the third quarter of 2022
September 22, 2022	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2022 PUMA BIOTECHNOLOGY, INC.
August 10, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 PUMA BIOTECHNOLOGY, INC.
August 4, 2022	EX-99.1	Puma Biotechnology Reports Second Quarter 2022 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2022 Financial Results LOS ANGELES, Calif., Aug. 4, 2022 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2022. Unless otherwise stated, all comparisons are for the second quarter of 2022 compared to the second quarter of 2021. Product revenue
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUM
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 PUMA BIOTECHNOLOGY, INC.
August 2, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 PUMA BIOTECHNOLOGY, INC.
August 2, 2022	424B3	PUMA BIOTECHNOLOGY, INC. 1,792,114 Shares of Common Stock Table of Contents PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-266306 PUMA BIOTECHNOLOGY, INC. 1,792,114 Shares of Common Stock The Selling Stockholder (as defined herein) may offer and sell up to 1,792,114 shares of common stock, par value $0.0001 per share, from time to time in one or more offerings. This prospectus provides you with a general description of the securities. W
July 28, 2022	CORRESP	Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 July 28, 2022 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tim Buchmiller Re: Puma Biotechnology, Inc. Registration Statement on Form S-3 (Registration No. 333-266306) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C
July 27, 2022	LETTER	LETTER United States securities and exchange commission logo July 27, 2022 Alan H. Auerbach President and Chief Executive Officer Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 Re: Puma Biotechnology, Inc. Registration Statement on Form S-3 Filed July 25, 2022 File No. 333-266306 Dear Mr. Auerbach: This is to advise you that we have not reviewed and will not r
July 25, 2022	S-3	As filed with the Securities and Exchange Commission on July 22, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 22, 2022 Registration No.
July 25, 2022	EX-10.1	Securities Purchase Agreement, dated March 8, 2022, by and between Puma Biotechnology, Inc. and the Purchasers listed on the Schedule of Purchasers thereto Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. PUMA BIOTECHNOLOGY, INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (?Agreement?) is made as of March 8, 2022 (the ?Agreement Date?), by
July 25, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Puma Biotechnology, Inc.
July 8, 2022	SC 13G	PBYI / Puma Biotechnology Inc / BlackRock Inc. Passive Investment us74587v1070070822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) PUMA BIOTECHNOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74587V107 - (CUSIP Number) June 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
June 17, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2022 PUMA BIOTECHNOLOGY, INC.
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 PUMA BIOTECHNOLOGY, INC.
May 5, 2022	EX-99.1	Puma Biotechnology Reports First Quarter 2022 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter 2022 Financial Results LOS ANGELES, Calif., May 5, 2022 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2022. Unless otherwise stated, all comparisons are for the first quarter of 2022 compared to the first quarter of 2021. Product revenue, ne
May 5, 2022	EX-10.1	Amended Non-Employee Director Compensation Program, dated April 27, 2022 (filed as Exhibit 10.1 to the Company’s Current Report on Form 10-Q filed with the SEC on May 5, 2022 and incorporated herein by reference) Exhibit 10.1 Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Effective April 27, 2022) Non-employee members of the board of directors (the ?Board?) of Puma Biotechnology, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in t
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PU
April 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 pbyi20211123def14a.htm FORM DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission
April 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 15, 2022	SC 13D/A	PBYI / Puma Biotechnology Inc / AUERBACH ALAN H - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) Alan H. Auerbach 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 Telephone : (424) 248-6500 Copy to : B
March 14, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 PUMA BIOTECHNOLOGY, INC.
March 14, 2022	EX-99.1	Puma Biotechnology Announces $10 Million Private Placement Exhibit 99.1 News Release Puma Biotechnology Announces $10 Million Private Placement LOS ANGELES, Calif., March 10, 2022 - Puma Biotechnology, Inc. (the Company) (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into a securities purchase agreement with Alan H Auerbach, the Company?s Chief Executive Officer, President and Chairman of the Board, as well as a fund of Athyriu
March 3, 2022	EX-10.18B	First Amendment to Note Purchase Agreement, dated February 8, 2022, by and between the Company and Athyrium Opportunities IV CO-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.18(b) to the Company’s Annual Report on Form 10-K filed with the SEC on March 3, 2022 and incorporated herein by reference) Exhibit 10.18(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. FIRST AMENDMENT TO NOTE DOCUMENTS This FIRST AMENDMENT TO NOTE DOCUMENTS (the ?Agreement?) dated as of February 8, 2022 is entered into by and among PUMA
March 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 PUMA BIOTECHNOLOGY, INC.
March 3, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934exhibit For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
March 3, 2022	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology Ltd England and Wales Puma Biotechnology B.V. Netherlands
March 3, 2022	EX-99.1	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results LOS ANGELES, Calif., March 3, 2022 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2021. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2021, compared to the four
February 14, 2022	SC 13G/A	PBYI / Puma Biotechnology Inc / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 CamberPBYI-202113G.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this S
February 14, 2022	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2022 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 11, 2022	SC 13G/A	PBYI / Puma Biotechnology Inc / Flynn James E Passive Investment SC 13G/A 1 e621313sc13ga-puma.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Puma Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587V107 (CUSIP Number) December 3
February 10, 2022	SC 13G/A	PBYI / Puma Biotechnology Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING PUMA BIOTECHNOLOGY INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 74587V107 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FI
February 10, 2022	SC 13G/A	PBYI / Puma Biotechnology Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Puma Biotechnology Inc. Title of Class of Securities: Common Stock CUSIP Number: 74587V107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is file
February 8, 2022	SC 13G	PBYI / Puma Biotechnology Inc / GOLDMAN SACHS GROUP INC - PUMA BIOTECHNOLOGY, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PUMA BIOTECHNOLOGY, INC. - (Name of Issuer) Common Stock, par value $0.0001 per share - (Title of Class of Securities) 74587V107 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
February 3, 2022	SC 13G/A	PBYI / Puma Biotechnology Inc / BlackRock Inc. Passive Investment us74587v1070020222.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) PUMA BIOTECHNOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74587V107 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
January 14, 2022	SC 13G	PBYI / Puma Biotechnology Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 74587V107 (CUSIP Number) JANUARY 6, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w
January 10, 2022	EX-99.1	Presentation of Puma Biotechnology, Inc., dated January 2022 Exhibit 99.1
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 PUMA BIOTECHNOLOGY, INC.
December 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 PUMA BIOTECHNOLOGY, INC.
November 19, 2021	SC 13G	PBYI / Puma Biotechnology Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 PBYISC13G2021.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 74587V107 (CUSIP Number) NOVEMBER 10, 2021 (Date of event which requires filing of this statement) Check the appropriate box to des
November 10, 2021	SC 13G/A	PBYI / Puma Biotechnology Inc / ALGER ASSOCIATES INC - PUMA BIOTECHNOLOGY, INC. Passive Investment Puma Biotechnology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Puma Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587V107 (CUSIP Number) October 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 PUMA BIOTECHNOLOGY, INC.
November 4, 2021	EX-10.1	Note Purchase Agreement, dated July 23, 2021, by and between the Company and Athyrium Opportunities IV Co-Invest 1 LP, as Administrative Agent (filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 4, 2021 and incorporated herein by reference) Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. THE NOTES ISSUED UNDER THIS NOTE PURCHASE AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR QUALIFIED
November 4, 2021	EX-1.1	Open Market Sale AgreementSM, dated November 4, 2021, by and between the Company and Jeffries LLC (filed as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 4, 2021 and incorporated herein by reference) EX-1.1 2 ex302823.htm EXHIBIT 1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM November 4, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Puma Biotechnology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agen
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3570
November 4, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 PUMA BIOTECHNOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35703 77-0683487 (State or Other Jurisdiction of Incorporation) (Commissi
November 4, 2021	EX-99.1	Puma Biotechnology Reports Third Quarter 2021 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2021 Financial Results LOS ANGELES, Calif., Nov. 4, 2021 - Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2021. Unless otherwise stated, all comparisons are for the third quarter of 2021 compared to the third quarter of 2020. Product revenu
November 4, 2021	424B5	$50,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-257687 PROSPECTUS SUPPLEMENT (To Prospectus dated July 13, 2021) $50,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the ?Sale Agreement?) with Jefferies LLC (?Jefferies?), relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accor
September 16, 2021	S-8	As filed with the Securities and Exchange Commission on September 16, 2021 As filed with the Securities and Exchange Commission on September 16, 2021 Registration No.
September 16, 2021	EX-99.12	Second Amendment to Puma Biotechnology, Inc. 2017 Incentive Award Plan (filed as Exhibit 99.12 to the Company's Current Report on Form S-8 filed with the SEC on September 16, 2021 and incorporated herein by reference) Exhibit 99.12 SECOND AMENDMENT TO THE PUMA BIOTECHNOLOGY, INC. 2017 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN THIS SECOND AMENDMENT TO THE PUMA BIOTECHNOLOGY, INC. 2017 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN (this ?Amendment?), effective as of July 15, 2021 (the ?Amendment Effective Date?), is made and adopted by the Board of Directors (the ?Board?) of Puma Biotechnology, Inc., a Delaware cor
September 16, 2021	EX-99.9	Form of Restricted Stock Unit Award Agreement, issued pursuant to the 2011 Incentive Award Plan Exhibit 99.9 PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Puma Biotechnology, Inc., a Delaware corporation, (the ?Company?), pursuant to its 2011 Incentive Award Plan (as may be amended from time to time, the ?Plan?), hereby grants to the holder listed below (the ?Participant?) an award of restricted stock units (the ?RSUs?). Each RSU represents the r
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, I
August 5, 2021	EX-99.1	Puma Biotechnology Reports Second Quarter 2021 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2021 Financial Results LOS ANGELES, Calif., Aug. 5, 2021 ? Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2021. Unless otherwise stated, all comparisons are for the second quarter of 2021 compared to the second quarter of 2020. Product revenue
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 PUMA BIOTECHNOLOGY, INC.
July 29, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2021 PUMA BIOTECHNOLOGY, INC.
July 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 PUMA BIOTECHNOLOGY, INC.
July 8, 2021	CORRESP	Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 Puma Biotechnology, Inc. 10880 Wilshire Boulevard, Suite 2150 Los Angeles, CA 90024 July 8, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Laura Crotty Re: Puma Biotechnology, Inc. Registration Statement on Form S-3 (Registration No. 333-257687) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of
July 8, 2021	LETTER	LETTER United States securities and exchange commission logo July 8, 2021 Maximo Nougues Chief Financial Officer Puma Biotechnology, Inc.
July 2, 2021	S-3	As filed with the Securities and Exchange Commission on July 2, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 2, 2021 Registration No.
June 25, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 PUMA BIOTECHNOLOGY, INC.
June 17, 2021	EX-10.1	Fifth Amendment to Puma Biotechnology, Inc. 2011 Incentive Award Plan (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 17, 2021 and incorporated herein by reference) Exhibit 10.1 FIFTH AMENDMENT TO PUMA BIOTECHNOLOGY, INC. 2011 INCENTIVE AWARD PLAN This Fifth Amendment (?Fifth Amendment?) to the Puma Biotechnology, Inc. 2011 Incentive Award Plan, as amended (the ?Plan?), is adopted by the Board of Directors (the ?Board?) of Puma Biotechnology, Inc., a Delaware corporation (the ?Company?), effective as of April 1, 2021 (the ?Effective Date?). Capitalized terms
June 17, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 PUMA BIOTECHNOLOGY, INC.
June 17, 2021	EX-4.1	Amendment to Warrant to Purchase Shares of Common Stock of Puma Biotechnology, Inc., dated April 1, 2021, by and between the Company and Alan H. Auerbach (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on June 17, 2021 and incorporated herein by reference) Exhibit 4.1 PUMA BIOTECHNOLOGY, INC. AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK THIS AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK (this ?Amendment?) is made as of April 1, 2021 (the ?Effective Date?), by and between Puma Biotechnology, Inc. (the ?Company?) and Alan H. Auerbach (the ?Holder?). Capitalized terms used and not otherwise defined herein shall have the meanings as
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 PUMA BIOTECHNOLOGY, INC.
May 6, 2021	EX-10.1	Fourth Amendment to Amended and Restated Loan and Security Agreement, dated February 3, 2021, by and between the Company and Oxford Finance LLC, as collateral agent and Lender Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. FOURTH AMENDMENT TO amended and restated LOAN AND SECURITY AGREEMENT THIS FOURTH AMENDMENT to Amended and Restated Loan and Security Agreement (this ?Amendmen
May 6, 2021	EX-10.2	Termination Agreement, dated February 24, 2021, by and between the Company and CANbridge BIOMED Limited (filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 6, 2021 and incorporated herein by reference) Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. TERMINATION AGREEMENT This TERMINATION AGREEMENT (this ?Agreement?) is made and entered into effective as of February 24, 2021 (the ?Effective Date?), by and
May 6, 2021	EX-10.3	Amendment No. 3 to the License Agreement, dated February 24, 2021, by and between the Company and Pierre Fabre Medicament SAS (filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 6, 2021 and incorporated herein by reference) Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Amendment n?3 to License Agreement This amendment n?3 (this ?Amendment?) is entered into as of February 24, 2021 (the ?Amendment 3 Effective Date?), by and be
May 6, 2021	EX-99.1	Puma Biotechnology Reports First Quarter 2021 Financial Results Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter 2021 Financial Results LOS ANGELES, Calif., May 6, 2021 ? Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparisons are for the first quarter of 2021 compared to the first quarter of 2020. Product revenue, ne
May 6, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY,
April 26, 2021	DEF 14A	Schedule 14A, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 26, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 2, 2021	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 29, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 PUMA BIOTECHNOLOGY, INC.
March 1, 2021	EX-10.1(D)	Amendment No. 2 to License Agreement dated October 29, 2020, between the Company and Pfizer Inc. (filed as Exhibit 10.1(d) to the Company's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and incorporated by reference) Exhibit 10.1(d) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. October 29, 2020 Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150 Los Angeles, CA 90024 Attention: Alan Auerbach Re:Amendment No. 2 to the License
March 1, 2021	EX-10.19	Letter Agreement, dated February 13, 2020, by and between the Company and Jeff J. Ludwig (filed as Exhibit 10.19 to the Company's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and incorporated herein by reference) Exhibit 10.19 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. February 13, 2020 Jeff J. Ludwig via E-mail Re:EMPLOYMENT OFFER LETTER Dear Jeff: Puma Biotechnology, Inc., a Delaware corporation (the ?Company?) is pleased
March 1, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNO
March 1, 2021	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology Ltd England and Wales Puma Biotechnology B.V. Netherlands
February 25, 2021	EX-99.1	# # # # # (Financial Tables Follow) Exhibit 99.1 News Release Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results LOS ANGELES, Calif., Feb. 25, 2021 ? Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2020, compared to the four
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 PUMA BIOTECHNOLOGY, INC.
February 23, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 PUMA BIOTECHNOLOGY, INC.
February 16, 2021	EX-1	JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 16, 2021 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers").
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Puma Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Dece Puma Biotechnology, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Puma Biotechnology, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendement No. 1) Puma Biotechnology, Inc (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendement No. 1) Puma Biotechnology, Inc (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Puma SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 11, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 PUMA BIOTECHNOLOGY, INC.
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Puma Biotechnology Inc. Title of Class of Securities: Common Stock CUSIP Number: 74587V107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is file
February 10, 2021	SC 13G	SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING PUMA BIOTECHNOLOGY INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 74587V107 (CUSIP NUMBER) 12/31/2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS
February 9, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Se UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) PUMA BIOTECHNOLOGY, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 74587V107 (CUSIP Number) DECEMBER 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate th
January 29, 2021	SC 13G/A	SC 13G/A us74587v1070012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) PUMA BIOTECHNOLOGY INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 74587V107 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 PUMA BIOTECHNOLOGY, INC.
November 5, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLO
November 5, 2020	EX-99.1	Puma Biotechnology Reports Third Quarter 2020 Financial Results EX-99.1 2 d70641dex991.htm EX-99.1 Exhibit 99.1 News Release Puma Biotechnology Reports Third Quarter 2020 Financial Results LOS ANGELES, Calif., Nov. 5, 2020 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2020. Unless otherwise stated, all comparisons are for the third quarter of 2020 compared to the th
August 10, 2020	SC 13G	PBYI / Puma Biotechnology Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
August 6, 2020	EX-10.3	Second Amendment to Amended and Restated Loan and Security Agreement, dated July 6, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender Exhibit 10.3 SECOND AMENDMENT TO amended and restated LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of July 6, 2020, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in su
August 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 PUMA BIOTECHNOLOGY, INC.
August 6, 2020	EX-10.4	Third Amendment to Amended and Restated Loan and Security Agreement, dated August 5, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender Exhibit 10.4 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. THIRD AMENDMENT TO amended and restated LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”
August 6, 2020	EX-99.1	Puma Biotechnology Reports Second Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 News Release Puma Biotechnology Reports Second Quarter 2020 Financial Results LOS ANGELES, Calif., Aug. 6, 2020 - Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to the second quarter of 2019. Product
August 6, 2020	EX-10.2	Pfizer Letter Agreement dated June 8, 2020, by and between the Company and Pfizer Inc. (filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 6, 2020 and incorporated herein by reference) Exhibit 10.2 Pfizer Inc. 500 Arcola Road Dock E – D 4214 Collegeville, PA 19426 [email protected] [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. June 8, 2020 Mr. Alan H. Auerbach (via Electronic Mail) Chief Execut
August 6, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, I
July 8, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2020 PUMA BIOTECHNOLOGY, INC.
June 30, 2020	EX-1	JOINT FILING AGREEMENT EX-1 2 PBYI13g2020ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated June 29, 2020 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securities and Exchan
June 30, 2020	SC 13G	PBYI / Puma Biotechnology Inc. / Camber Capital Management LLC - PRIMARY DOCUMENT Passive Investment SC 13G 1 camberPBYI-202013g.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Puma Biotechnology, Inc (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) June 18, 2020 (Date of Event Which Requires Filing of this Statement) Check the appro
June 12, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 PUMA BIOTECHNOLOGY, INC.
June 11, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 PUMA BIOTECHNOLOGY, INC.
May 7, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2020 PUMA BIOTECHNOLOGY, INC.
May 7, 2020	EX-99.1	Puma Biotechnology Reports First Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 News Release Puma Biotechnology Reports First Quarter 2020 Financial Results LOS ANGELES, Calif., May 7, 2020 – Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2020. Unless otherwise stated, all comparisons are for the first quarter of 2020 compared to the first quarter of 2019. Product rev
May 7, 2020	EX-10.3	Amended Non-Employee Director Compensation Program (filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 7, 2020 and incorporated herein by reference) Exhibit 10.3 Puma Biotechnology, Inc. Non-Employee Director Compensation Program (Effective January 1, 2020) Non-employee members of the board of directors (the “Board”) of Puma Biotechnology, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in
May 7, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY,
April 27, 2020	DEF 14A	- DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 27, 2020	DEFA14A	- DEFA14A DEFA14A 1 d900277ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
March 26, 2020	SC 13G	PBYI / Puma Biotechnology Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Puma Biotechnology, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 74587V107 (CUSIP Number) March 16, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
March 23, 2020	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2020 PUMA BIOTECHNOLOGY, INC.
March 4, 2020	EX-10.1	First Amendment to Amended and Restated Loan and Security Agreement, dated February 27, 2020, by and between the Company and Oxford Finance LLC, as collateral agent and Lender EX-10.1 Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Amended and Restated Loan and Security Agreement (this “Am
March 4, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 PUMA BIOTECHNOLOGY, INC.
February 28, 2020	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNO
February 28, 2020	EX-10.18(C)	Second Amendment to the License Agreement, dated November 25, 2019, by and between the Company and Pierre Fabre Medicament SAS (filed as Exhibit 10.18(c) to the Company’s Annual Report on Form 10-K filed with the SEC on February 28, 2020 and incorporated herein by reference) Exhibit 10.18(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment (the “Second Amendment”), effective as of November 25, 2019 (“Effective Date of the Second Ame
February 28, 2020	EX-21.1	Puma Biotechnology, Inc. Exhibit 21.1 Puma Biotechnology, Inc. Subsidiaries Subsidiary Jurisdiction of Incorporation or Organization Puma Biotechnology Ltd England and Wales Puma Biotechnology B.V. Netherlands
February 28, 2020	EX-10.17(B)	Amendment to the License Agreement, dated December 18, 2019, by and between the Company and Knight Therapeutics, Inc. (filed as Exhibit 10.17(b) to the Company’s Annual Report on Form 10-K filed with the SEC on February 28, 2020 and incorporated herein by reference) EX-10.17(B) 3 pbyi-ex1017b376.htm EX-10.17(B) Exhibit 10.17(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. AMENDING AGREEMENT Nerlynx License Agreement THIS AGREEMENT made effective as of the 18th day of December, 2
February 28, 2020	EX-10.18(B)	First Amendment to the License Agreement, dated September 17, 2019, by and between the Company and Pierre Fabre Medicament SAS (filed as Exhibit 10.18(b) to the Company’s Annual Report on Form 10-K filed with the SEC on February 28, 2020 and incorporated herein by reference) Exhibit 10.18(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment (the “First Amendment”), effective as of September 17, 2019 (“Effective Date of the First Amendm

PBYI / Puma Biotechnology, Inc. - SEC申報文件，年度報告，委任書

基本數據

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?